Table 4: Clinical Trial and Guideline Basis for Compelling Indications for Individual Drug Classes

Table 4:
Clinical Trial and Guideline Basis for Compelling Indications for Individual Drug Classes
Compelling Indication*	Recommended Drugs†						Clinical Trial Basis ‡
Compelling Indication*							Clinical Trial Basis ‡
Heart failure	X	X	X	X		X	ACC/AHA Heart Failure Guideline, MERIT-HF, COPERNICUS, CIBIS, SOLVD, AIRE, TRACE, ValHEFT, RALES
Postmyocardial infarction		X	X			X	ACC/AHA Post-MI Guideline, BHAT, SAVE, Capricorn, EPHESUS
High coronary disease risk	X	X	X		X		ALLHAT, HOPE, ANBP2, LIFE, CONVINCE
Diabetes	X	X	X	X	X		NKF-ADA Guideline, UKPDS, ALLHAT
Chronic kidney disease			X	X			NKF Guideline, Captopril Trial, RENAAL, IDNT, REIN, AASK
Recurrent stroke prevention	X		X				PROGRESS
* Compelling indications for antihypertensive drugs are based on benefits from outcome studies or existing clinical guidelines; the compelling indication is managed in parallel with the BP. † Drug abbreviations: BB=beta-blocker; ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; CCB=calcium channel blocker; Aldo ANT=aldosterone antagonist ‡ Conditions for which clinical trials demonstrate benefit of specific classes of antihypertensive drugs. Adapted from JNC VII